Former OpenAI Science Lead Reportedly Launches Warp Sciences to Automate Wet Labs With Robots

TechCrunch reported on October 22, 2026, that former OpenAI science lead Kevin Weil had launched Warp Sciences.

According to TechCrunch, Warp Sciences plans to use robots to automate wet-lab work and handle experimental tasks for drug discovery. If the concept takes shape, automation of repetitive tasks early in the drug discovery process will be a key issue.

What is new in this report is the launch of a company focused on automating wet labs with robots, under Kevin Weil's name. The report centers on the company's formation and fundraising; it is not a primary source detailing equipment configurations or operating specifications. For now, the public information goes only as far as a plan to use robots to carry out experimental work. See the original report for details. Our related coverage, OpenAI reportedly signals timing for humanoid robot unveiling and Report on DeepSeek and OpenAI's entry into embodied AI, pointed to growing interest in robotics and embodied AI around OpenAI. Warp Sciences appears to be part of that broader trend, but it does not directly indicate a change in OpenAI's business. It should instead be viewed as a case of a former executive pursuing experimental automation through a separate company. The industry's key question is whether AI applications will expand from model development to repetitive laboratory work. However, TechCrunch's report alone does not make clear which experimental processes the company plans to automate, or how it will distinguish itself from existing contract testing and synthesis services. The next points to watch are the scope of the tasks assigned to robots, the experimental conditions handled in wet labs, and disclosures about operations after the funding round.

If there are implications for Japan, they would be for industries around the robots, measurement equipment and reagent handling used in drug discovery support and experimental automation. However, this report does not specify which processes are targeted, so concrete effects on Japanese companies cannot be determined.